Leap Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
My name is Emily Bodnar and I'm an equity research analyst at H.C. Wainwright. I'm pleased to introduce our next presenter, Doug Onsi, who is the Chief Executive Officer of Leap Therapeutics.
Thank you. It's a pleasure to be here virtually at the H.C. Wainwright 25th Annual Investment Conference. I'm Doug Onsi, the President and CEO of Leap Therapeutics. And I'm proud to be able to give you an update on the clinical development of DKN-01 and the milestones ahead in the coming months. My presentation will include forward-looking statements. So I encourage you to review our securities acts filings.
Leap Therapeutics is a biomarker-driven oncology drug development company with a strategic focus on gastrointestinal cancers. We're developing a pipeline of targeted and immuno-oncology antibody therapeutics led by DKN-01, our Anti-DKK1 monoclonal antibody that has generated single-agent activity in three different tumor types. Compelling combination activity with anti-PD-1 and PD-L1 antibodies and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |